Literature DB >> 25916224

Consecutive Monitoring of Fecal Calprotectin and Lactoferrin for the Early Diagnosis and Prediction of Pouchitis after Restorative Proctocolectomy for Ulcerative Colitis.

Takayuki Yamamoto1, Takahiro Shimoyama1, Takuya Bamba1, Koichi Matsumoto1.   

Abstract

OBJECTIVES: This prospective study was conducted to evaluate the significance of consecutive monitoring of fecal calprotectin and lactoferrin for the early diagnosis and prediction of pouchitis after restorative proctocolectomy for ulcerative colitis (UC).
METHODS: Sixty patients who had ileostomy closure following total proctocolectomy and ileal pouch-anal anastomosis for UC were included. Stool samples were collected for the measurement of calprotectin and lactoferrin every 2 months up to 12 months after the ileostomy closure. When patients had symptoms suggestive of pouchitis, endoscopic examination was immediately undertaken. All asymptomatic patients underwent endoscopy at 12 months. Pouchitis was defined as a pouchitis disease activity index score of ≥7.
RESULTS: During the 12 months, 10 patients (17%) developed pouchitis. In patients with pouchitis, fecal calprotectin and lactoferrin levels were elevated already 2 months before the diagnosis of pouchitis. In contrast, these fecal biomarkers remained at low levels, and they did not change significantly in patients without pouchitis. A cutoff value of 56 μg/g for calprotectin had a sensitivity of 100% and a specificity of 84% to predict pouchitis, whereas a cutoff value of 50 μg/g for lactoferrin had a sensitivity of 90% and a specificity of 86%. At the time of endoscopy, the median calprotectin and lactoferrin levels were significantly higher in patients with pouchitis than those without pouchitis.
CONCLUSIONS: Elevated fecal calprotectin and lactoferrin levels appeared to be significant predictors of pouchitis after restorative proctocolectomy for UC. Consecutive monitoring of these fecal biomarkers is useful for the early diagnosis of pouchitis.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25916224     DOI: 10.1038/ajg.2015.129

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  19 in total

1.  Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study.

Authors:  A G Røseth; M K Fagerhol; E Aadland; H Schjønsby
Journal:  Scand J Gastroenterol       Date:  1992-09       Impact factor: 2.423

Review 2.  Ileal j pouch complications and surgical solutions: a review.

Authors:  Jingjing Sherman; Adrian J Greenstein; Alexander J Greenstein
Journal:  Inflamm Bowel Dis       Date:  2014-09       Impact factor: 5.325

Review 3.  Clinical utility of fecal biomarkers for the diagnosis and management of inflammatory bowel disease.

Authors:  Uri Kopylov; Greg Rosenfeld; Brian Bressler; Ernest Seidman
Journal:  Inflamm Bowel Dis       Date:  2014-04       Impact factor: 5.325

4.  Comparison of six different calprotectin assays for the assessment of inflammatory bowel disease.

Authors:  Delphine Labaere; Annick Smismans; August Van Olmen; Paul Christiaens; Geert D'Haens; Veerle Moons; Pieter-Jan Cuyle; Johan Frans; Peter Bossuyt
Journal:  United European Gastroenterol J       Date:  2014-02       Impact factor: 4.623

5.  A simple method for assessing intestinal inflammation in Crohn's disease.

Authors:  J Tibble; K Teahon; B Thjodleifsson; A Roseth; G Sigthorsson; S Bridger; R Foster; R Sherwood; M Fagerhol; I Bjarnason
Journal:  Gut       Date:  2000-10       Impact factor: 23.059

6.  Assessment of ileal pouch inflammation by single-stool calprotectin assay.

Authors:  P Thomas; H Rihani; A Røseth; G Sigthorsson; A Price; R J Nicholls; I Bjarnason
Journal:  Dis Colon Rectum       Date:  2000-02       Impact factor: 4.585

7.  Pouchitis after ileal pouch-anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis.

Authors:  C Penna; R Dozois; W Tremaine; W Sandborn; N LaRusso; C Schleck; D Ilstrup
Journal:  Gut       Date:  1996-02       Impact factor: 23.059

8.  Fecal lactoferrin for diagnosis of symptomatic patients with ileal pouch-anal anastomosis.

Authors:  Mansour A Parsi; Bo Shen; Jean-Paul Achkar; Feza F Remzi; John R Goldblum; James Boone; Dahai Lin; Jason T Connor; Victor W Fazio; Bret A Lashner
Journal:  Gastroenterology       Date:  2004-05       Impact factor: 22.682

9.  Diagnosing pouchitis: comparative validation of two scoring systems in routine follow-up.

Authors:  Udo A Heuschen; Erik H Allemeyer; Ulf Hinz; Frank Autschbach; Tanja Uehlein; Christian Herfarth; Gundi Heuschen
Journal:  Dis Colon Rectum       Date:  2002-06       Impact factor: 4.585

10.  Faecal calprotectin: a noninvasive diagnostic tool and marker of severity in pouchitis.

Authors:  Matt W Johnson; Susan Maestranzi; Audrey M Duffy; David H Dewar; Alastair Forbes; Ingvar Bjarnason; Roy A Sherwood; Paul Ciclitira; John R Nicholls
Journal:  Eur J Gastroenterol Hepatol       Date:  2008-03       Impact factor: 2.566

View more
  14 in total

1.  Can Fecal Biomarkers Detect Ileal Inflammation in Inflammatory Bowel Disease?

Authors:  Takayuki Yamamoto; Takahiro Shimoyama
Journal:  Am J Gastroenterol       Date:  2015-09       Impact factor: 10.864

2.  Serial monitoring of faecal calprotectin for the assessment of endoscopic recurrence in asymptomatic patients after ileocolonic resection for Crohn's disease: a long-term prospective study.

Authors:  Takayuki Yamamoto; Takahiro Shimoyama; Satoru Umegae; Koichi Matsumoto
Journal:  Therap Adv Gastroenterol       Date:  2016-05-01       Impact factor: 4.409

Review 3.  Fecal calprotectin: its scope and utility in the management of inflammatory bowel disease.

Authors:  Shapur Ikhtaire; Mohammad Sharif Shajib; Walter Reinisch; Waliul Islam Khan
Journal:  J Gastroenterol       Date:  2016-02-20       Impact factor: 7.527

4.  Serial Fecal Calprotectin and Lactoferrin Measurements for Early Diagnosis of Pouchitis After Proctocolectomy for Ulcerative Colitis: Is Pouchoscopy No Longer Needed?

Authors:  Alain Schoepfer; Walter Reinisch
Journal:  Am J Gastroenterol       Date:  2015-06       Impact factor: 10.864

5.  Combined Endoscopic and Oral Fecal Microbiota Transplantation in Patients with Antibiotic-Dependent Pouchitis: Low Clinical Efficacy due to Low Donor Microbial Engraftment.

Authors:  Hans Herfarth; Edward L Barnes; Millie D Long; Kim L Isaacs; Tom Leith; Michael Silverstein; Ylaine Gerardin; Zain Kassam
Journal:  Inflamm Intest Dis       Date:  2019-03-29

Review 6.  Relevance of fecal calprotectin and lactoferrin in the post-operative management of inflammatory bowel diseases.

Authors:  Roberta Caccaro; Imerio Angriman; Renata D'Incà
Journal:  World J Gastrointest Surg       Date:  2016-03-27

7.  Ustekinumab Is Effective for the Treatment of Chronic Antibiotic-Refractory Pouchitis.

Authors:  Jacob E Ollech; David T Rubin; Laura Glick; Roni Weisshof; Katia El Jurdi; Amanda Israel; Noa Krugliak Cleveland; Neil Hyman; Atsushi Sakuraba; Joel Pekow; Russell D Cohen; Sushila R Dalal
Journal:  Dig Dis Sci       Date:  2019-06-11       Impact factor: 3.199

8.  International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases.

Authors:  Ferdinando D'Amico; David T Rubin; Paulo Gustavo Kotze; Fernando Magro; Britta Siegmund; Taku Kobayashi; Pablo A Olivera; Peter Bossuyt; Lieven Pouillon; Edouard Louis; Eugeni Domènech; Subrata Ghosh; Silvio Danese; Laurent Peyrin-Biroulet
Journal:  United European Gastroenterol J       Date:  2021-05-07       Impact factor: 4.623

Review 9.  Expert opinion for use of faecal calprotectin in diagnosis and monitoring of inflammatory bowel disease in daily clinical practice.

Authors:  Catherine Reenaers; Peter Bossuyt; Pieter Hindryckx; Hilde Vanpoucke; Anneline Cremer; Filip Baert
Journal:  United European Gastroenterol J       Date:  2018-06-20       Impact factor: 4.623

Review 10.  Chronic Antibiotic-Refractory Pouchitis: Management Challenges.

Authors:  An Outtier; Marc Ferrante
Journal:  Clin Exp Gastroenterol       Date:  2021-06-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.